Drug Profile
Research programme: siRNA cancer therapeutics - Quark Pharmaceuticals
Latest Information Update: 18 Feb 2020
Price :
$50
*
At a glance
- Originator Quark Pharmaceuticals
- Class Antineoplastics; Small interfering RNA
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
- 17 Nov 2015 Early research in Sarcoma in USA (Parenteral)
- 31 Aug 2010 Preclinical development is ongoing USA